If you're attending ICML in Lugano, Switzerland, then drop by the ESMO booth, next to Auditorium A. We'd love to see you!
Find out why you should join, what you will gain and how to apply to become a member of ESMO.
Annals of Oncology, our official journal, publishes editorials, reviews, original articles and letters related to oncology.
OncologyPRO is our scientific information and education portal, designed to help you keep up to date with the latest research and clinical information.
L. Licitra shares her comments about randomised, phase III DECISION trial that studied sorafenib, an orally active inhibitor of VEGFR1-3 and Raf kinases, vs. placebo in patients with progressive locally advanced/metastatic radioactive iodine-refractory differentiated thyroid cancer. The standard treatment in this situation is a classical chemotherapy and now targeted therapy with sorafenib shows improved progression-free survival with tolerability consistent with known sorafenib safety profile. http://www.esmo.org
19 Jun 2013 / Scientific news
In-depth look at public participation in medical research across the United States
18 Jun 2013 / Scientific news
EMUC 2013 - 5th European Multidisciplinary Meeting on Urological Cancers, 15-17 November 2013 Marseille, France
18 Jun 2013 / ESMO News
Application deadline for this fellowship is 20 June 2013. Apply now!
17 Jun 2013 / Scientific news
Laying down biomarkers for future cancer treatments
13 Jun 2013 / Scientific news
Read and comment on the latest Journal Club article written by Ozan Yazici and Omer Dizdar
06 Jun 2013 / Scientific news
Lipegfilgrastim is intended for prophylaxis against chemotherapy-induced neutropenia
Barcelona, Spain
03 Jul
- 06 Jul
2013
Amsterdam, Netherlands
27 Sep
- 01 Oct
2013
Marseille, France
15 Nov
- 17 Nov
2013
Milan, Italy
18 Feb
- 19 Feb
2014
Geneva, Switzerland
26 Mar
- 29 Mar
2014
Brussels, Belgium
08 May
- 10 May
2014
